Navigation Links
Patheon to Host Complimentary Seminar on “Formulation, Funding and First-in-Man: A Stepwise Guide to Clinical Success”
Date:6/4/2013

(PRWEB) June 04, 2013

Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced that it will be hosting a complimentary seminar on “Formulation, Funding and First-in-Man: A Stepwise Guide to Clinical Success”. The seminar will be held on Tuesday, June 25, 2013 at 11:30 a.m. to 5:30 p.m. Central European Time at the Hilton Hotel in Basel, Switzerland.

In the upcoming seminar, Patheon has invited four scientific leaders to share their experiences and answer questions on successfully progressing to, as well as advancing beyond first-in-man studies. Presentations will be provided by Patheon employees, Jon Sutch, Ph.D., and Roman Hlodan, Ph.D., as well as from Massimo Bresciani from Research Center Pharmaceutical Engineering GmbH, Austria, and Fintan Walton, Ph.D., from PharmaVentures Ltd., UK.

Through case studies and interactive presentations, presenters will discuss formulation strategies to progress to first-in-man for solid, sterile and biopharmaceutical products. In addition, Dr. Walton will present strategies to maximizing the value of an asset from the perspective of an investor.

Visit the company’s website at http://www.patheon.com/Knowledge-Library/Events.aspx to learn more or register for the upcoming seminar. Seating is limited.

About Patheon

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 17 locations, including 13 commercial contract manufacturing facilities and 12 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit http://www.patheon.com.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10788543.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
2. Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
3. Patheon to Present at Informex USA
4. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
5. Patheon to Present at 2013 DCAT Week
6. Patheon to Present New Updates in Drug Formulation and Bioavailability
7. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
8. Patheon to Showcase High Potency Capabilities at Upcoming Tradeshows
9. Patheon to Feature its Complex Formulation Technologies Expertise at the Upcoming CPhI – P-MEC –ICSE – BioPh – Pharmatec – Medtec Japan – Conference
10. Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing”
11. Patheon to Host Webinar on “Accelerating the Drug Development Trajectory by Improving Solubility of New Compounds”
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ca (PRWEB) , ... October 12, 2017 , ... ... the Surgical Wound Market with the addition of its newest module, US Hemostats ... $1.2B market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
Breaking Biology Technology:
(Date:10/4/2017)...  GCE Solutions, a global clinical research organization (CRO), announces the ... on October 4, 2017. Shadow is designed to assist medical writers ... 0070 of the European Medicines Agency (EMA) in meeting the requirements ... ... ...
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO®). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
Breaking Biology News(10 mins):